Magdi Nagy

Post doc

Dr. Magdolna Nagy earned her bachelor's and master's degrees in Clinical Laboratory Sciences at the University of Debrecen, Hungary. She completed her PhD at CARIM, under the guidance of Prof. Johan Heemskerk, Prof. Judith Cosemans, and Prof. Steve Watson (Birmingham, UK), focusing on new patwhays in thrombus formation pathways. During her PhD, she made significant contributions to understanding the intricate mechanisms of thrombus formation by better understanding how blood platelet regulate this process in interaction with vessel wall components, the blood plasma and leukocytes.

After her PhD, she joined the group of Prof. Hugo ten Cate and Prof. Henri Spronk at CARIM as postdoctoral fellow in the clinical thrombosis and haemostasis lab. She worked as part of the Cardiovascular Moonshot of RegMed Consortium where she focused on studying the impact of (anti)coagulation on cardiac regenerative therapy aiming to restore the heart function ex vivo.  In 2019, she received a Contrast Young Investigator Grant from the NHS supported CONTRAST Consortium to investigate the role of the intrinsic activation of coagulation in ischemia reperfusion injury in acute ischemic stroke.

Magdolna is currently working as a researcher within the group of Prof Henri Spronk. In 2022, she was awared with the  prestigous Dr E Dekker postdoctoral grant from the Dutch Heart Foundation for her project focusing on unravelling the impact of contact activation pathway in acute ischemic stroke. Furthermore, she is investigating the alteration of coagulation in atrial fibrillation and the roles of coagulation factor XI in heamostasis and beyond.

Magdi nagy

Department of Biochemistry
Universiteitssingel 50, 6229 ER Maastricht
Room number: H1.314
T: +31(0)43 388 42 63

  • 2026
    • Leader, A., Wolach, O., Gavrieli, B., Elitzur, S., Spronk, H. M. H., Nagy, M., van Oerle, R., Spectre, G., Shimony, S., Moshe, Y., Mahajna, R., Martin, L., Gilad, G., Gilead, O., Avrahami, G., Izraeli, S., Raanani, P., & Barzilai-Birenboim, S. (2026). Ex Vivo Thrombin Generation Assessment of Four Anticoagulants in Children with Acute Lymphoblastic Leukemia. Pediatric Hematology and Oncology, 43(8), 488-501. https://doi.org/10.1080/08880018.2026.2750854
    • Bondi, E., Obino, G., Guidotti, G., Sensini, A., Nagy, M., Spronk, H. M. H., van Griensven, M., Lepedda, A. J., Lotti, N., & Moroni, L. (2026). Aromatic Copolyesters Based on Poly(butylene furanoate) and Poly(butylene isophthalate) for Small-Diameter Vascular Applications. ACS Biomaterial Science and Engineering, 12(7), 3557-3568. https://doi.org/10.1021/acsbiomaterials.6c00106
    • Schellens, J., Nagy, M., Hulshof, A. M., van Rosmalen, F., van Oerle, R., van Herpt, T. T. W., Alnima, T., Mulder, M. M. G., Hellenbrand, D., ten Cate, H., Driessen, R. G. H., Sels, J. W. E. M., van der Horst, I. C. C., Henskens, Y. M. C., van Bussel, B. C. T., Spronk, H. M. H., & Dutch Covid and Thrombosis Coalition (2026). Inhibition of inflammation reduces hypofibrinolysis in severe COVID-19: A nested case-control study within the MaastrICCht cohort. Thrombosis Research, 262, Article 109723. https://doi.org/10.1016/j.thromres.2026.109723
    • Urlings, E. H., Heubel-Moenen, F. C. J. I., van Oerle, R., Hellenbrand, D. L. S., van der Meijden, P. E. J., Hackeng, T. M., Cate, H. T., Nagy, M., Henskens, Y. M. C., & Spronk, H. M. H. (2026). Intrinsic activated thrombin generation for treatment efficacy and monitoring of octocog alfa and emicizumab in severe hemophilia A. Research and practice in thrombosis and haemostasis, 10(4), Article 106627. https://doi.org/10.1016/j.rpth.2026.106627
    • ten Cate, V., Sulochana, H. R., ten Cate, H., & Nagy, M. (2026). Coagulation factor XI and cardiovascular disease: A complex, cardio-specific conundrum. Med, 7(2), Article 100995. https://doi.org/10.1016/j.medj.2025.100995
    • Nagy, M., Gomes, T., Van Oerle, R., Hacking, T. M., Magdelijns, F. J. H., Henskens, Y. M. C., Reitsma, P., Short, G., Spronk, H. M. H., & Verhoef, D. (2026). Coagulation assays for assessing the bypassing of factor Xa direct oral anticoagulants using VMX-C001. Research and practice in thrombosis and haemostasis, 10(2), Article e103375. https://doi.org/10.1016/j.rpth.2026.103375
    • Verburg, A., Bor, W., Nagy, M., Spronk, H. M. H., Cate, H. T., Hackeng, C., & Berg, J. T. (2026). Coagulation dynamics during coronary angiography in patients receiving chronic direct oral anticoagulants: insights from the randomized POPular MEASURE study. Journal of Thrombosis and Haemostasis. Advance online publication. https://doi.org/10.1016/j.jtha.2026.09.026
  • 2025
    • Obino, G., Nieddu, G., Nagy, M., Ippel, H., Cubeddu, T., Spronk, H. M. H., Hackeng, T. M., Formato, M., Lepedda, A. J., & Moroni, L. (2025). Marine-derived sulfated polysaccharides enhance hemocompatibility and endothelialization of nanofibrous PCL for vascular graft applications. Cell Biomaterials, 1(10), Article 100155. https://doi.org/10.1016/j.celbio.2025.100155
    • D'Italia, G., Coenen, D. M., Lemmens, T. P., Brandts, L., Wielders, S. J. H., Nagy, M., Mourmans, S. G. J., Achten, A., Al-Abadi, A., Weerts, J., Aizpurua, A. B., van Empel, V., Schroen, B., & Cosemans, J. M. E. M. (2025). Immuno-haemostatic dysregulation in heart failure with preserved ejection fraction. Esc heart failure, 12(5), 3444-3460. https://doi.org/10.1002/ehf2.15361
    • Wang, M., Taha, A., Nagy, M., Raben, J. D., van Noort, R., Volovici, V., Dammers, R., Duncker, D. J., Spronk, H., Ten Cate, H., Dippel, D., Bobi, J., & van Beusekom, H. M. M. (2025). Microvascular Occlusion and Postrecanalization Hyperperfusion in a Swine Model of Acute Ischemic Stroke. Journal of the American Heart Association, 14(18), Article e042663. https://doi.org/10.1161/JAHA.125.042663